Shelton Wealth Management LLC Acquires 5,237 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Shelton Wealth Management LLC grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 77.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,969 shares of the medical equipment provider’s stock after purchasing an additional 5,237 shares during the quarter. Shelton Wealth Management LLC’s holdings in Lantheus were worth $1,071,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC acquired a new stake in Lantheus during the 3rd quarter worth $1,066,000. Massachusetts Financial Services Co. MA bought a new position in Lantheus during the third quarter worth about $25,955,000. Van ECK Associates Corp grew its stake in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the period. Finally, Swedbank AB raised its position in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

LNTH opened at $91.47 on Friday. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The firm has a market cap of $6.36 billion, a P/E ratio of 15.22 and a beta of 0.46. The business’s fifty day moving average is $89.72 and its 200-day moving average is $99.85.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LNTH shares. Truist Financial reissued a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.